TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28457562

Group type: EXPERIMENTAL
Intervention: Reveal LINQ™ ICM implantation in a procedure room
Number of subjects: 1420

Group type: EXPERIMENTAL
Intervention: Reveal LINQ™ ICM implantation in an electrophysiology laboratory
Number of subjects: 1420

Group type: EXPERIMENTAL
Intervention: Patients requiring device repositioning
Number of subjects: 1420

Group type: EXPERIMENTAL
Intervention: Patients not requiring device repositioning
Number of subjects: 1420

Group type: EXPERIMENTAL
Intervention: Overall AEs with device explantation
Number of subjects: 1420

Group type: EXPERIMENTAL
Intervention: Overall AEs without device explantation
Number of subjects: 1420

Group type: COMPARATOR
Intervention: Patients undergoing implantation in a procedure room
Number of subjects: 1420

Group type: COMPARATOR
Intervention: Patients undergoing implantation in an electrophysiology laboratory
Number of subjects: 1420
Study: 25512417

Group type: EXPERIMENTAL
Intervention: 100 mg/kg of eflornithine every 6 h for 14 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 125 mg/kg of eflornithine every 6 h for 14 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both dosages of eflornithine
Number of subjects: 25
Study: 24205183

Group type: EXPERIMENTAL
Intervention: ART for >12 weeks
Number of subjects: 165

Group type: COMPARATOR
Intervention: ART for ≤12 weeks
Number of subjects: 165
Study: 21732833

Group type: EXPERIMENTAL
Intervention: Rifapentine (900 mg) plus isoniazid (900 mg) weekly for 12 weeks
Number of subjects: 1148

Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg) plus isoniazid (900 mg) twice weekly for 12 weeks
Number of subjects: 1148

Group type: EXPERIMENTAL
Intervention: Isoniazid (300 mg) daily for up to 6 years (continuous isoniazid)
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Isoniazid (300 mg) daily for 6 months (control group)
Number of subjects: 1148
Study: 19467054

Group type: EXPERIMENTAL
Intervention: EMDgel (Emdogain)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Calcium hydroxide [Ca(OH)(2)]
Number of subjects: 15

Group type: COMPARATOR
Intervention: Both groups (EMDgel and Ca(OH)(2))
Number of subjects: 15
Study: 16708123

Group type: EXPERIMENTAL
Intervention: Pycnogenol 150 mg or 300 mg daily for 8 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Daflon 1,000 mg/day
Number of subjects: 86
Study: 16279275

Group type: EXPERIMENTAL
Intervention: Complete case analysis
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Imputation using baseline values or worst case value
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Repeated measures analysis
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Last observation carried forward
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Imputation with worst case value
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Imputation using regression predictions
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis
Number of subjects: 71
Study: 11152792

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography (MIP images)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography (reformatted transverse source images)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional angiography
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MIP images
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Source images
Number of subjects: 50
Study: 9266231

Group type: EXPERIMENTAL
Intervention: Alfuzosin 2.5 mg t.i.d. for 4 weeks
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Alfuzosin (single-blind) during the 8-week extension period
Number of subjects: 94
Study: 8336198

Group type: EXPERIMENTAL
Intervention: 2.5 mg alendronate
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 5 mg alendronate
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 10 mg alendronate (2-hour infusion)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 10 mg alendronate (24-hour infusion)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 15 mg alendronate
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: >= 5 mg alendronate
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 59
Study: 6355263

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nafcillin
Number of subjects: 200
Study: 31614946

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (9 months)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Detraining (3 months)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Normal activities (Control Group)
Number of subjects: 47
Study: 28881359

Group type: EXPERIMENTAL
Intervention: Repeat HPV-negative test in HPV-positive women with normal cytology
Number of subjects: 9279

Group type: COMPARATOR
Intervention: HPV-negative women with normal cytology (double negatives)
Number of subjects: 9279
Study: 25843603

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement varnish
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control (no varnish)
Number of subjects: 480
Study: 24729994

Group type: EXPERIMENTAL
Intervention: Virtual reality simulator training (16 hours)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 18
Study: 22074059

Group type: EXPERIMENTAL
Intervention: Cabergoline (0.25 mg twice weekly for 4 weeks followed by 0.5 mg twice weekly for the next 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19649245

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01B
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A
Number of subjects: 255

Group type: COMPARATOR
Intervention: Rabies vaccine (Rabipur; Chiron Behring GmbH)
Number of subjects: 255
Study: 18091519

Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Everolimus 3 mg/day
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Everolimus (both dosages)
Number of subjects: 634

Group type: COMPARATOR
Intervention: AZA
Number of subjects: 634
Study: 16857508

Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOL (AcrySof MA60, Alcon)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Plate-haptic silicone IOL (C11UB, Chiron)
Number of subjects: 35
Study: 12764713

Group type: EXPERIMENTAL
Intervention: Benzodiazepine Dependence Self-Report Questionnaire (Bendep-SRQ)
Number of subjects: 180
Study: 10100071

Group type: EXPERIMENTAL
Intervention: alpha 2 exon 21-22 marker
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: alpha 2 haplotype
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: beta 1 Msp I marker
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: beta 1 haplotype
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: beta 1 markers
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: alpha 2 exon 21-22 genotype
Number of subjects: 533
Study: 8738670

Group type: EXPERIMENTAL
Intervention: Sandimmun Optoral
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sandimmun
Number of subjects: 28
Study: 1930075

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (3.3 mg/kg body weight)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 6349363

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin suppressive therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Close surveillance
Number of subjects: 200
Study: 31074779

Group type: EXPERIMENTAL
Intervention: Effect allele of rs1051730
Number of subjects: 393122
Study: 29044133

Group type: EXPERIMENTAL
Intervention: High water availability (W+)
Number of subjects: 737

Group type: COMPARATOR
Intervention: Low water availability (W-)
Number of subjects: 737
Study: 26374140

Group type: EXPERIMENTAL
Intervention: Daily supplementation with antioxidant nutrients (vitamin C 120 mg, β-carotene 6 mg, vitamin E 30 mg, selenium 100 µg, zinc 20 mg)
Number of subjects: 3966
Study: 23256821

Group type: EXPERIMENTAL
Intervention: Fluid ingestion (FL) - 5 ml kg(‐1) before and 2 ml kg(‐1) every 15 min
Number of subjects: 8

Group type: COMPARATOR
Intervention: No fluid ingestion (NF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluid ingestion (FL)
Number of subjects: 8
Study: 21739689

Group type: EXPERIMENTAL
Intervention: Penetrating needling on head points (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acupuncture of syndrome division (group B)
Number of subjects: 60
Study: 19306364

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.1 mmol/kg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (0.1 mmol/kg)
Number of subjects: 46
Study: 16858271

Group type: EXPERIMENTAL
Intervention: CMV prophylaxis
Number of subjects: 0
Study: 12742010

Group type: EXPERIMENTAL
Intervention: Azithromycin (500mg/day for 3 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline measurements of CSA disposition kinetics (before azithromycin treatment)
Number of subjects: 8
Study: 10701036

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9377958

Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative external-beam radiation (EBR) of the bronchial stump and mediastinum (50 to 56 Gy, 8 or 23 MV photons, 2 Gy/d, 5 d/wk)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative external-beam radiation (EBR)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (no further treatment)
Number of subjects: 155
Study: 1492845

Group type: EXPERIMENTAL
Intervention: Dimetindene maleate (DMM)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3903788

Group type: EXPERIMENTAL
Intervention: Combination of 20 mg penbutolol plus 3 mg piretanide
Number of subjects: 51

Group type: COMPARATOR
Intervention: 40 mg penbutolol alone
Number of subjects: 51
Study: 30922609

Group type: EXPERIMENTAL
Intervention: 7-session modified mindfulness-based cognitive therapy over 10 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual family care and brief education on dementia care
Number of subjects: 36
Study: 28265119

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 27031740

Group type: EXPERIMENTAL
Intervention: Severe normobaric hypoxia (SH; FiO2 = 13.3%; 3600 m)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Moderate normobaric hypoxia (MH; FiO2 = 16.8%; corresponding to 1800 m)
Number of subjects: 13
Study: 25211921

Group type: EXPERIMENTAL
Intervention: Phytodrug prolit super septo 2 capsules 2 times a day for 4 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard therapy only
Number of subjects: 66
Study: 21393260

Group type: EXPERIMENTAL
Intervention: Graded running programme with additional shockwave therapy (ESWT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Graded running programme
Number of subjects: 42
Study: 20538001

Group type: EXPERIMENTAL
Intervention: DFMO/sulindac
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 17851941

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency-induced thermotherapy (RFITT)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Standard blunt dissection tonsillectomy (TE)
Number of subjects: 137
Study: 15681169

Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid (AA) administration up to four times within 12 hours based on initial AA concentration (4x500 mg AA for <34.1 micromol/l; 2x500 mg AA for < or =56.8 micromol/l; 1x500 mg AA for < or =68.2 micromol/l)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 57
Study: 11413075

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg per day for 4 weeks
Number of subjects: 15
Study: 9916387

Group type: EXPERIMENTAL
Intervention: Emtrexate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Methotrexate Remedica
Number of subjects: 10

Group type: COMPARATOR
Intervention: Methotrexate Lederle
Number of subjects: 10
Study: 8063993

Group type: EXPERIMENTAL
Intervention: Enhanced Family Treatment (EFT)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Standard Family Treatment (SFT)
Number of subjects: 147
Study: 3142454

Group type: EXPERIMENTAL
Intervention: Experimental group (12 young men) using a device supplying 12.8% O2 for 7.5-8 hours daily for 10 days.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (10 young men) using a placebo device breathing normoxic air.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups exposed to 4500 m altitude after treatment.
Number of subjects: 22
Study: 29872148

Group type: EXPERIMENTAL
Intervention: TEFOX regimen (docetaxel 50 mg/m2, oxaliplatin 85 mg/m2, 5FU 2400 mg/m2) administered every 14 days
Number of subjects: 65
Study: 28131948

Group type: EXPERIMENTAL
Intervention: internet‐based cognitive behavioural therapy (ICBT)
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: usual care (CBT or supportive counselling)
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: exercise
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: high availability of relationships
Number of subjects: 946

Group type: COMPARATOR
Intervention: low availability of relationships
Number of subjects: 946
Study: 25939030

Group type: EXPERIMENTAL
Intervention: Expressive Writing (EW)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Nonemotional Writing Instructions (Control)
Number of subjects: 146
Study: 23293111

Group type: EXPERIMENTAL
Intervention: Sequential docetaxel (A (75 mg/m(2)) × 3 → docetaxel (T (100 mg/m(2)) × 3 → CMF)
Number of subjects: 2887

Group type: COMPARATOR
Intervention: Sequential control (doxorubicin (A) (75 mg/m(2)) × 4 → CMF)
Number of subjects: 2887
Study: 20826055

Group type: EXPERIMENTAL
Intervention: Advisor‐Teller Money Manager (ATM) treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Minimal‐attention control condition
Number of subjects: 90
Study: 18056743

Group type: EXPERIMENTAL
Intervention: Topical ibuprofen
Number of subjects: 282

Group type: COMPARATOR
Intervention: Oral ibuprofen
Number of subjects: 282
Study: 16601430

Group type: EXPERIMENTAL
Intervention: 100 mg PPS 3 times per day (300 mg/day)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 200 mg PPS 3 times per day (600 mg/day)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo 3 times per day
Number of subjects: 168
Study: 12830443

Group type: EXPERIMENTAL
Intervention: Short daily HD
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Long nocturnal HD
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional HD
Number of subjects: 45
Study: 10877245

Group type: EXPERIMENTAL
Intervention: 10% (w/w) glycolic acid scalp lotion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.1% (w/w) betamethasone scalp application
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of 10% glycolic acid lotion and 0.1% betamethasone
Number of subjects: 20
Study: 8704119

Group type: EXPERIMENTAL
Intervention: Fish oil (30% C20:5 omega‐3 and 20% C22:6 omega‐3) at 6 g/day for 3 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Coconut oil (63% C8:0 and 36% C10:0) at 6 g/day for 3 months (Control)
Number of subjects: 25
Study: 1948127

Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Interferon/dexamethasone
Number of subjects: 505

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 505
Study: 6832206

Group type: EXPERIMENTAL
Intervention: Plain uncoated tablet (400 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sustained-release tablet formulation 1 (400 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sustained-release tablet formulation 2 (400 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous aminophylline
Number of subjects: 12
Study: 31207146

Group type: EXPERIMENTAL
Intervention: LUS (lung ultrasound)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 442
Study: 27802155

Group type: EXPERIMENTAL
Intervention: Vedolizumab (VDZ) therapy
Number of subjects: 41
Study: 27958325

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (100 U)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (100 U) in dysfunctional voiding patients
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (normal saline) in dysfunctional voiding patients
Number of subjects: 62
Study: 24857821

Group type: EXPERIMENTAL
Intervention: sibutramine
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: shCBT + sibutramine
Number of subjects: 104

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 104

Group type: COMPARATOR
Intervention: shCBT + placebo
Number of subjects: 104
Study: 23400973

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Capsaicin (Myolaxin ointment)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: EMLA + capsaicin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (plain lubricant cream)
Number of subjects: 120
Study: 20153216

Group type: EXPERIMENTAL
Intervention: Subcutaneous LMWH 40 mg once per day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subcutaneous LMWH 40 mg twice per day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study: 18076018

Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 127

Group type: COMPARATOR
Intervention: Toupet fundoplication
Number of subjects: 127
Study: 15717259

Group type: EXPERIMENTAL
Intervention: Immunoadjuvant prednisolone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12678152

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prednisolone acetate
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prednisolone acetate and fluorometholone acetate
Number of subjects: 120
Study: 10673992

Group type: EXPERIMENTAL
Intervention: Relaxation training with guided imagery and L-arginine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (dietary supplementation)
Number of subjects: 96
Study: 8694083

Group type: EXPERIMENTAL
Intervention: Excimer laser phototherapeutic keratectomy
Number of subjects: 211
Study: 1922173

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) injection
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 42
Study: 6354122

Group type: EXPERIMENTAL
Intervention: Hospital-based program to improve pneumococcal immunization; Duration: Two successive winters.
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Documentation of prior hospitalization within five years among adults with pneumococcal bacteremia; Population size: 61 adults.
Number of subjects: 1062
Study: 6140351

Group type: EXPERIMENTAL
Intervention: General Health Questionnaire (GHQ) results made available to physicians (experimental group)
Number of subjects: 1452

Group type: COMPARATOR
Intervention: No GHQ results made available to physicians (control group)
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Patients with a prior diagnosis of a mental disorder
Number of subjects: 1452
Study: 29981778

Group type: EXPERIMENTAL
Intervention: Test toothpaste containing 0.454% stannous fluoride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control fluoride toothpaste containing 0.76% sodium monofluorophosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mineral water
Number of subjects: 0
Study: 27440084

Group type: EXPERIMENTAL
Intervention: S100A9 variant rs3014866 T carriers
Number of subjects: 2684

Group type: EXPERIMENTAL
Intervention: High SFA:carbohydrate intake in CC carriers
Number of subjects: 2684

Group type: COMPARATOR
Intervention: Low SFA:carbohydrate intake in CC carriers
Number of subjects: 2684
Study: 24446062

Group type: EXPERIMENTAL
Intervention: LCZ696 100 mg
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: LCZ696 200 mg
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: LCZ696 400 mg
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: LCZ696 (all doses)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study: 20561282

Group type: COMPARATOR
Intervention: High-intensity exercise (HE)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Moderate-intensity exercise (ME)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No exercise/rest (NE)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Recovery after exercise
Number of subjects: 90
Study: 27365744

Group type: EXPERIMENTAL
Intervention: Technique using face-bow
Number of subjects: 20

Group type: COMPARATOR
Intervention: Technique avoiding face-bow
Number of subjects: 20
Study: 18498914

Group type: EXPERIMENTAL
Intervention: Cefteram pivoxil powder suspension (100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cefteram pivoxil tablet (100 mg)
Number of subjects: 24
Study: 15619278

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Minimally invasive direct coronary artery bypass (MIDCAB)
Number of subjects: 189
Study: 12645861

Group type: EXPERIMENTAL
Intervention: Flt3 ligand (20 microg/kg per day) administered subcutaneously daily for 14 days on a 28‐day cycle, monthly for four months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flt3 ligand with the E75 peptide vaccine administered on day 7 of each flt3 ligand cycle
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flt3 ligand with the E75 peptide vaccine administered on day 14 of each flt3 ligand cycle
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: E75 peptide admixed with granulocyte‐macrophage colony‐stimulating factor and administered intradermally once every 28 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study: 10573704

Group type: EXPERIMENTAL
Intervention: Tazocillin (4 g piperacillin and 0.5 g tazobactam)
Number of subjects: 10
Study: 8909760

Group type: EXPERIMENTAL
Intervention: Biocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Jelonet
Number of subjects: 0
Study: 1873241

Group type: EXPERIMENTAL
Intervention: Oxytocin 5 IU
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sulprostone 500 micrograms
Number of subjects: 74

Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 74